Active substance (DCI)
- durvalumab
history (10)
-
4/4/24
IMFINZI (durvalumab) - Cancer bronchique non à petites cellules
-
10/12/23
IMFINZI (durvalumab) - Cancer des voies biliaires
-
8/30/23
IMFINZI / TREMELIMUMAB ASTRAZENECA (durvalumab / tremelimumab) - Metastatic non-small cell lung cancer (NSCLC)
CAV : -
6/21/23
IMFINZI (durvalumab) - Biliary tract cancer
CAV : -
5/24/23
IMFINZI (durvalumab) and IMJUDO (tremelimumab) - Hepatocellular carcinoma (HCC)
CAV : -
2/23/23
IMFINZI (durvalumab) - Carcinome hépato-cellulaire